<DOC>
	<DOCNO>NCT00624052</DOCNO>
	<brief_summary>The primary objective trial ass efficacy safety fix dose combination telmisartan 40mg/amlodipine 10mg ( T40/A10 ) telmisartan 80mg/amlodipine 10mg ( T80/A10 ) open-label treatment least six month . An additional objective ass efficacy safety concomitant administration either T40/A10 T80/A10 therapies commonly use treatment hypertension . The primary endpoint proportion patient achieve DBP control ( define mean seat DBP &lt; 90 mmHg trough i.e . approximately 24 hour last dose study treatment ) six month treatment last trough observation treatment period ( i.e . last trough observation carry forward ) .</brief_summary>
	<brief_title>26-week Open Study telmisartan40mg+amlodipine10mg telmisartan80mg+amlodipine10 mg Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>diagnosis essential hypertension pregnancy , breastfeeding , unwilling use effective contraception ( female childbearing potential ) . development condition precede trial could worsen telmisartan 40mg/amlodipine 10mg ( T40/A10 ) telmisartan 80mg/amlodipine 10mg ( T80/A10 ) . discontinuation precede trial . know suspected secondary hypertension . mean seat systolic blood pressure ( SBP ) &gt; = 180 mmHg and/or mean seat diastolic blood pressure ( DBP ) &gt; = 120 mmHg visit . clinically significant hepatic impairment severe renal impairment bilateral renal artery stenosis renal artery stenosis solitary kidney post postrenal transplant . clinically relevant hyperkalaemia . uncorrected volume sodium depletion . primary aldosteronism . hereditary fructose lactose intolerance . symptomatic congestive heart failure . patient previously experience symptom characteristic angioedema treatment angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARBs ) . new drug alcohol dependency since sign consent precede trial . concurrent participation another clinical trial investigational therapy since complete precede trial . hypertrophic obstructive cardiomyopathy , hemodynamically relevant stenosis aortic mitral valve . know allergic hypersensitivity component formulation investigation . [ Includes know hypersensitivity telmisartan ARBs amlodipine dihydropyridine calcium channel blocker ( CCBs ) . ] noncompliance study medication ( define &lt; 80 % &gt; 120 % ) precede trial . administration ARBs dihydropyridine CCBs ( apart trial medication ) . clinical condition , opinion investigator , would allow safe completion protocol safe administration telmisartan amlodipine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>